证券代码：688152 证券简称：麒麟信安 公告编号：2025-098 湖南麒麟信安科技股份有限公司 第二届董事会第二十六次会议决议的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 该议案已经公司第二届独立董事专门委员会第三次会议审议通过。具体内容 详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《湖南麒麟信安 科技股份有限公司关于 2026 年度日常关联交易预计的公告》（公告编号： 2025-095）。 （二）审议通过《关于修订<公司章程>并办理工商变更登记的议案》 鉴于公司已完成 2024 年限制性股票激励计划首次授予部分第一个归属期的 股份归属登记工作，本次归属股票来源为公司向激励对象定向发行的公司人民币 A 股普通股股票，归属数量为 749,813 股。本次限制性股票归属后，公司股本总 数已由 102,080,546 股增加至 102,830,359 股。为此，董事会一致同意对《公司章 程》中相关条款进行修订，并提请股东会授权公司管理层或其授权代表办理相关 工商变更 ...

证券代码：688152 证券简称：麒麟信安 公告编号：2025-094 湖南麒麟信安科技股份有限公司关于持股 5%以上 股东权益变动触及 1%刻度的提示性公告 3. 一致行动人信息 公司董事、总经理刘文清先生及其一致行动人瑞昌捷清创业投资合伙企业（有限 合伙）保证向本公司提供的信息真实、准确、完整，没有虚假记载、误导性陈述或重大 遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 重要内容提示： | 权益变动方向 | 比例增加□ | | 比例减少 | | --- | --- | --- | --- | | 权益变动前合计比例 | 12.43% | | | | 权益变动后合计比例 | 12.00% | | | | 本次变动是否违反已作出的承 诺、意向、计划 | 是□ | 否 | | | 是否触发强制要约收购义务 | 是□ | 否 | | 一、信息披露义务人及其一致行动人的基本信息 1.身份类别 | | □控股股东/实际控制人及其一致行动人 其他 5%以上大股东及其一致行动人 | | --- | --- | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅 ...

（原标题：麒麟信安(688152.SH)：瑞昌捷清合计减持44.47万股公司股份） 格隆汇12月25日丨麒麟信安(688152.SH)公布，公司于近日收到股东瑞昌捷清创业投资合伙企业（有限 合伙）（以下简称"瑞昌捷清"）出具的《告知函》，2025年11月25日至2025年12月25日，瑞昌捷清通过 集中竞价交易方式合计减持公司股份44.47万股，占公司当前总股本的比例为0.43%。 ...

麒麟信安公告称，2025年11月25日至12月25日，股东瑞昌捷清通过集中竞价交易减持44.47万股，占总 股本0.43%。本次权益变动后，瑞昌捷清及其一致行动人刘文清合计持股由1278.42万股降至1233.95万 股，占比由12.43%降至12.00%，触及1%刻度整数倍。此次变动系履行减持计划，未实施完毕，不会导 致实控人变化，也不涉及披露权益变动报告书。 ...

证券日报网讯 12月16日，麒麟信安在互动平台回答投资者提问时表示，近两年公司暂无产品直接出口 欧盟国家的相关业务。公司现阶段业务重心主要聚焦国内市场，同时依托集成商合作伙伴出口业务，实 现产品及服务在"一带一路"国家的应用，公司暂未直接开展出口海外的业务。 （文章来源：证券日报） ...

格隆汇12月16日丨麒麟信安(688152.SH)在投资者互动平台表示，近两年公司暂无产品直接出口欧盟国 家的相关业务。公司现阶段业务重心主要聚焦国内市场，同时依托集成商合作伙伴出口业务，实现产品 及服务在"一带一路"国家的应用，公司暂未直接开展出口海外的业务。 ...

格隆汇12月16日丨麒麟信安(688152.SH)在投资者互动平台表示，目前公司暂无自有AI容器产品。 ...

格隆汇12月16日丨麒麟信安(688152.SH)在投资者互动平台表示，目前公司暂无自有AI容器产品。 ...

Group 1 - Jicheng Electronics won a total of 15 bids from the State Grid Corporation, with a total bid amount of approximately 215 million yuan, accounting for 8.27% of the company's projected revenue for 2024 [2] - Jianmin Group's chemical generic drug, Ambrutoro Oral Solution, has been approved for market launch by the National Medical Products Administration, aimed at treating cough and wheezing caused by chronic bronchitis and emphysema [3] - Taiji Industry's subsidiary plans to transfer accounts receivable not exceeding 85 million USD to optimize cash flow, with an expected service fee of approximately 285,000 USD [4] Group 2 - Nanjing Pharmaceutical's subsidiary plans to invest 398 million yuan in a modern pharmaceutical logistics expansion project, with a construction period of approximately 35 months [5] - Ruili Kemi received a development notification from a well-known domestic flying car company to supply core components [6] - Ding Tong Technology announced that several executives plan to reduce their holdings by a total of no more than 45,300 shares, representing about 0.032% of the total share capital [7][8] Group 3 - Ninghu Expressway's subsidiary plans to invest no more than 9.033 billion yuan in the construction of the Nanyang Yangtze River Bridge South Connection Project [10] - Wuliangye announced a mid-term profit distribution plan for 2025, proposing a cash dividend of 25.78 yuan per 10 shares, totaling approximately 10 billion yuan [12] - Beixin Road and Bridge's subsidiary won a bid for a project worth 180 million yuan [14] Group 4 - Minhe Livestock reported a 7.75% month-on-month increase in sales revenue from commodity chick sales in November [15] - Xuelong Group plans to invest 100 million yuan to establish a wholly-owned subsidiary for vertical integration in the aluminum and magnesium technology sector [16] - Shengnong Development reported a 15.77% year-on-year increase in sales revenue in November, with significant growth in both poultry and processed meat products [17] Group 5 - Xingyu Co., Ltd. plans to repurchase shares worth 200 million to 300 million yuan for employee stock ownership plans [18] - Quan Chai Power intends to use 50 million yuan of idle funds to purchase structured deposit products [19] - Shibei High-tech appointed Zhao Junhong as the new deputy general manager [20] Group 6 - Fuan Pharmaceutical's subsidiary received a drug registration certificate for injectable isavuconazole, expanding its anti-infection product line [21] - Xiaoming Co. reported a 49.73% year-on-year decline in chicken product sales revenue in November [22] - Baiao Chemical adjusted its share repurchase price ceiling to no more than 48.95 yuan per share [23] Group 7 - Hefei China reported a 26.02% year-on-year decline in consolidated revenue for the first 11 months [24] - Laimei Pharmaceutical's subsidiary received medical device registration certificates for two endoscope products [25][26] - Xiantan Co. reported an 11.63% year-on-year increase in chicken product sales revenue in November [27] Group 8 - Qilin Security received government subsidies totaling 5.4014 million yuan [28] - Blue Sky Gas's controlling shareholder's 30.9134 million shares were judicially frozen, accounting for 4.33% of the total share capital [29] - Tieke Railway signed a contract for high-speed railway fasteners worth 654 million yuan, accounting for 41.08% of the company's projected revenue for 2024 [30] Group 9 - David Medical's electric surgical table received a medical device registration certificate [31] - Zhendong Pharmaceutical's affiliate's core product new drug application was accepted by the CDE [32] - Shanghai Pharmaceutical's apple acid sitagliptin tablet application for market approval was granted by the National Medical Products Administration [33] Group 10 - Nanjiao Food reported a 1.14% year-on-year increase in consolidated revenue for November [34]

一、获得补助的基本情况 特此公告。 湖南麒麟信安科技股份有限公司（以下简称"公司"）近日收到政府补助款项 合计 540.14 万元，属于与收益相关的政府补助款项。 湖南麒麟信安科技股份有限公司 董事会 二、补助的类型及其对公司的影响 根据《企业会计准则第 16 号-政府补助》的有关规定，公司获得的上述政府 补助属于与收益相关的政府补助。上述政府补助未经审计，具体的会计处理及对 公司 2025 年度损益的影响，最终以审计机构年度审计确认后的结果为准，敬请 投资者注意投资风险。 证券代码：688152 证券简称：麒麟信安 公告编号：2025-093 湖南麒麟信安科技股份有限公司 关于获得政府补助的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 2025 年 12 月 11 日 ...